• cbdMD reached a definitive asset purchase agreement to acquire Twinlab operating assets and brands via an assignment for the benefit of creditors process.
• Portfolio includes Twinlab, Reserveage, Metabolife, Alvita Tea, expanding into legacy supplements, sports nutrition, beauty, weight loss, longevity.
• Combined unaudited trailing 12-month revenue through June 2026 estimated at about $30 million, roughly 40% above cbdMD standalone.
• Deal aims to reduce reliance on hemp-derived products, broadening into a multi-brand consumer wellness platform.
• Closing remains subject to court approval and customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-029455), on September 02, 2026, and is solely responsible for the information contained therein.